IMBRUVICA 140 mg hard capsules, Calquence 100 mg film-coated tablets, Calquence 100 mg hard capsules, IMBRUVICA 140 mg hard capsules
ACE-CL-006
Phase 3 small_molecule active
Quick answer
IMBRUVICA 140 mg hard capsules, Calquence 100 mg film-coated tablets, Calquence 100 mg hard capsules, IMBRUVICA 140 mg hard capsules for High Risk Chronic Lymphocytic Leukaemia is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- High Risk Chronic Lymphocytic Leukaemia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active